- Home
- TIL vs ESPR Comparison
TIL vs ESPR Comparison
Compare TIL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- ESPR
- Stock Information
- Founded
- TIL 2018
- ESPR 2008
- Country
- TIL United States
- ESPR United States
- Employees
- TIL N/A
- ESPR N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- ESPR Health Care
- Exchange
- TIL Nasdaq
- ESPR Nasdaq
- Market Cap
- TIL 230.1M
- ESPR 220.0M
- IPO Year
- TIL 2021
- ESPR 2013
- Fundamental
- Price
- TIL $31.69
- ESPR $1.51
- Analyst Decision
- TIL Buy
- ESPR Buy
- Analyst Count
- TIL 5
- ESPR 6
- Target Price
- TIL $119.00
- ESPR $6.50
- AVG Volume (30 Days)
- TIL 263.6K
- ESPR 4.8M
- Earning Date
- TIL 08-12-2025
- ESPR 08-05-2025
- Dividend Yield
- TIL N/A
- ESPR N/A
- EPS Growth
- TIL N/A
- ESPR N/A
- EPS
- TIL N/A
- ESPR N/A
- Revenue
- TIL N/A
- ESPR $259,574,000.00
- Revenue This Year
- TIL N/A
- ESPR $5.15
- Revenue Next Year
- TIL N/A
- ESPR N/A
- P/E Ratio
- TIL N/A
- ESPR N/A
- Revenue Growth
- TIL N/A
- ESPR 12.99
- 52 Week Low
- TIL $9.85
- ESPR $0.69
- 52 Week High
- TIL $92.00
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- TIL 60.55
- ESPR 71.94
- Support Level
- TIL $25.58
- ESPR $1.13
- Resistance Level
- TIL $32.76
- ESPR $2.08
- Average True Range (ATR)
- TIL 2.55
- ESPR 0.15
- MACD
- TIL 0.75
- ESPR 0.03
- Stochastic Oscillator
- TIL 89.55
- ESPR 41.84
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.